SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Claud B who wrote (6468)5/5/1999 2:40:00 PM
From: Diamondcutter  Read Replies (2) | Respond to of 7041
 
Lehman's drug analyst wrote up a summary of the various erectile disfunction presenters (SGP, TAP and ICOS)--I don't know if they all came from the pre seminar seminar or just Vasomax. I'd post details, but 80% of the board would not believe it. FWIW, the analyst concluded the drug peak potential to be near $500m annually (sales) at under $7 per pill.



To: Claud B who wrote (6468)5/5/1999 3:26:00 PM
From: Bob Trocchi  Respond to of 7041
 
Claud...

>>SGP DID present data on Vasomax at a seminar just prior to the
AUA meeting in Dallas. <<

And???????

Bob T.



To: Claud B who wrote (6468)5/5/1999 3:33:00 PM
From: BDR  Read Replies (1) | Respond to of 7041
 
<< SGP DID present data on Vasomax at a seminar just prior to the
AUA meeting in Dallas. >>

Zonagen DID have a booth at the AUA two years ago, they were handing out the results of the small trial of Vasomax in Mexico and there may have been a paper presented at the meeting as well. The Vasomax data submitted to the FDA has been presented at various urology meetings around the country. Vasomax is not a secret.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News